HK1210414A1 - 治療皮膚疤痕的組合物和方法 - Google Patents

治療皮膚疤痕的組合物和方法

Info

Publication number
HK1210414A1
HK1210414A1 HK15111150.6A HK15111150A HK1210414A1 HK 1210414 A1 HK1210414 A1 HK 1210414A1 HK 15111150 A HK15111150 A HK 15111150A HK 1210414 A1 HK1210414 A1 HK 1210414A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treating cutaneous
cutaneous scarring
scarring
Prior art date
Application number
HK15111150.6A
Other languages
English (en)
Inventor
Cynthia Lander
Colleen Brophy
Caryn Peterson
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of HK1210414A1 publication Critical patent/HK1210414A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15111150.6A 2012-09-10 2015-11-11 治療皮膚疤痕的組合物和方法 HK1210414A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699160P 2012-09-10 2012-09-10
US13/829,876 US20140072613A1 (en) 2012-09-10 2013-03-14 Compositions and Methods for Treating Cutaneous Scarring
PCT/US2013/059060 WO2014040074A2 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Publications (1)

Publication Number Publication Date
HK1210414A1 true HK1210414A1 (zh) 2016-04-22

Family

ID=50233502

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15111150.6A HK1210414A1 (zh) 2012-09-10 2015-11-11 治療皮膚疤痕的組合物和方法
HK15111211.3A HK1210422A1 (zh) 2012-09-10 2015-11-13 治療皮膚疤痕的組合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15111211.3A HK1210422A1 (zh) 2012-09-10 2015-11-13 治療皮膚疤痕的組合物和方法

Country Status (14)

Country Link
US (1) US20140072613A1 (zh)
EP (1) EP2892546A4 (zh)
JP (1) JP6247692B2 (zh)
KR (1) KR102040710B1 (zh)
CN (1) CN105120886A (zh)
AU (1) AU2013312120B2 (zh)
CA (1) CA2884264A1 (zh)
GB (1) GB2520897B (zh)
HK (2) HK1210414A1 (zh)
MX (1) MX368878B (zh)
NZ (1) NZ705743A (zh)
RU (2) RU2019126644A (zh)
SG (1) SG11201501818VA (zh)
WO (1) WO2014040074A2 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3643782A1 (en) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
CN105131067B (zh) 2010-03-24 2019-02-19 雷克西制药公司 皮肤与纤维化症候中的rna干扰
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
WO2014110177A2 (en) 2013-01-09 2014-07-17 International Stem Cell Corporation Small molecules that promote skin regeneration
JP6772062B2 (ja) * 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
SG11201705559RA (en) 2015-01-08 2017-08-30 Moerae Matrix Inc Formulation of mk2 inhibitor peptides
US9999655B2 (en) 2015-03-12 2018-06-19 Moerae Matrix, Inc. Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
CN104689301A (zh) * 2015-03-27 2015-06-10 吴开刚 一种祛除妊娠纹的药物及其制备方法
JP7187310B2 (ja) * 2015-10-08 2022-12-12 エーエムディー セラピューティックス エルエルシー Ｖｅｇｆ阻害剤の局所投与による皮膚障害の処置
CN105709270B (zh) * 2016-03-18 2019-01-01 中国科学院长春应用化学研究所 一种用于干细胞治疗的水凝胶敷料
JP6815782B2 (ja) * 2016-07-29 2021-01-20 小林製薬株式会社 α−ＳＭＡ産生抑制剤
US11697813B2 (en) 2016-10-30 2023-07-11 Sirnaomics, Inc. Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
KR101921727B1 (ko) * 2016-12-28 2018-11-23 주식회사 제네웰 실리콘 수지 조성물, 이의 제조방법 및 이를 포함하는 흉터 치료제
CN111163784A (zh) * 2017-09-01 2020-05-15 黄玲惠 用于治疗蟹足肿的药物组合物及其用途
US10485755B1 (en) * 2018-02-05 2019-11-26 Wade Cheng Formulation and method for treatment of non-acne scars
WO2019154963A1 (en) * 2018-02-09 2019-08-15 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for monitoring scar development
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
WO2019222520A1 (en) * 2018-05-16 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation
CN111558128A (zh) * 2019-03-26 2020-08-21 华中科技大学同济医学院附属协和医院 一种载瘢痕修复药物的可溶性微针阵列及制备方法
WO2020210382A1 (en) * 2019-04-08 2020-10-15 The General Hospital Corporation Enhancement of melanocyte migration using rock inhibitors
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing
CN114072163A (zh) * 2019-05-09 2022-02-18 芝加哥大学 皮肤伤口愈合和瘢痕预防的新材料
RU2712183C1 (ru) * 2019-09-30 2020-01-24 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения пациентов с рубцовыми поражениями кожи
CN110917179B (zh) * 2019-12-19 2021-04-27 温州医科大学附属第一医院 一种抗疤痕硅凝胶贴及其制备方法
KR102584738B1 (ko) * 2020-01-17 2023-10-06 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물
US20210318587A1 (en) * 2020-04-13 2021-10-14 Massachusetts Institute Of Technology Melanin-peptide-based photonic materials
CN112425560A (zh) * 2020-10-27 2021-03-02 纳肽得有限公司 皮肤增生性瘢痕动物模型及其构建方法
CN117295512A (zh) * 2021-05-03 2023-12-26 爱恩斯生物有限公司 用于改善瘢痕和瘢痕瘤的包含zag衍生的肽的组合物
EP4376907A1 (en) * 2021-07-30 2024-06-05 The Board of Trustees of the Leland Stanford Junior University Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same
CN117304303A (zh) * 2023-07-14 2023-12-29 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2200557C1 (ru) * 2001-11-23 2003-03-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н.Федорова Способ лечения гипертрофических и келоидных рубцов
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
ES2476842T3 (es) 2007-01-10 2014-07-15 Purdue Research Foundation Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos
WO2008109794A2 (en) 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
US8999377B2 (en) * 2007-09-19 2015-04-07 Surmodics, Inc. System for forming a biocompatible foam using polymerizable alpha(1-4)glucopyranose polymers and gas-producing component
JP2011507862A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
JP5785085B2 (ja) * 2008-10-20 2015-09-24 モイライ マトリックス インコーポレイテッド 癒着を処置又は防止するためのポリペプチド
CN102316731B (zh) 2008-12-10 2016-06-01 普渡研究基金会 基于细胞渗透性肽的激酶抑制剂
WO2010098760A1 (en) * 2009-02-26 2010-09-02 Hewlett-Packard Development Company, L.P. Void pantographs and methods for generating the same
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
JP6071875B2 (ja) * 2010-06-18 2017-02-08 ザ ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレイティド 毛包新生
WO2012082950A2 (en) * 2010-12-14 2012-06-21 University Of Rochester Chimeric fibronectin matrix mimetics and uses thereof
MX365647B (es) * 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.

Also Published As

Publication number Publication date
AU2013312120B2 (en) 2018-04-19
SG11201501818VA (en) 2015-04-29
WO2014040074A3 (en) 2014-06-26
MX2015003075A (es) 2016-02-05
GB2520897B (en) 2020-07-01
RU2705211C2 (ru) 2019-11-06
US20140072613A1 (en) 2014-03-13
KR20150100615A (ko) 2015-09-02
EP2892546A4 (en) 2016-07-13
CA2884264A1 (en) 2014-03-13
NZ705743A (en) 2018-08-31
AU2013312120A1 (en) 2015-03-26
JP6247692B2 (ja) 2017-12-13
HK1210422A1 (zh) 2016-04-22
GB2520897A (en) 2015-06-03
RU2015113011A (ru) 2016-11-10
EP2892546A2 (en) 2015-07-15
JP2015533798A (ja) 2015-11-26
RU2019126644A (ru) 2019-09-19
MX368878B (es) 2019-10-21
CN105120886A (zh) 2015-12-02
WO2014040074A2 (en) 2014-03-13
KR102040710B1 (ko) 2019-11-05
GB201505972D0 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
HK1210422A1 (zh) 治療皮膚疤痕的組合物和方法
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
HK1209798A1 (zh) 用於治療癌症的組合物和方法
IL269166A (en) Methods and preparations for treating inflammation
EP2916876A4 (en) METHOD AND COMPOSITIONS FOR WOUND HEALING
EP2836482A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
HK1201475A1 (zh) 治療疼痛的方法和組合物
EP2890720A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
EP2950884A4 (en) COMPOSITIONS AND METHOD FOR TREATING SURFACES
DK3292875T3 (en) Compositions and methods for treating diseases
HK1208598A1 (zh) 治療疼痛的方法及組合物
HK1216854A1 (zh) 用於治療癌症的組合物和方法
EP2863939A4 (en) COMPOSITIONS AND METHODS FOR TREATING VITILIGO
LT2863931T (lt) Kompozicijos, skirtos panaudoti žaizdų gydymui
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2822593A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP2800763A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
EP2718427A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLIOBLASTOMES
EP2714082A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
ZA201408732B (en) Composition and methods for treating wounds